Brought to you by 
Genta, Aventis sign $480mm antisense deal; ended
10 Nov 2004
Executive Summary
In the largest biotech alliance announced so far this year, Genta (cancer therapeutics) and Aventis will co-develop Genta's lead program Genasense (oblimersen sodium), an antisense product that is in several Phase III trials in combination with chemotherapy drugs to treat solid tumors and cancers of the blood.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Antisense, Oligonucleotides
- Large Molecule
Deal Status
- Terminated
Deal Type
-
Alliance
- Co-Promotion
- Includes Contract
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Genta, Aventis sign $480mm antisense deal; ended
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice